For the aging consumer over 60, the morning ritual of mixing a protein shake has long been a compromise between digestive comfort and physiological efficacy. For decades, the market has been bifurcated: animal-derived whey protein offered proven muscle synthesis, while plant-based alternatives were often dismissed as insufficient for combating age-related muscle loss. This tension between preference and performance has left a significant gap in the nutritional landscape for seniors. This week, the conversation shifts as Nuritas prepares to present clinical data at Vitafoods Europe 2026 that could redefine the standard for plant-based muscle support.
The Architecture of the PeptiStrong Clinical Trial
Nuritas is centering its presence at Vitafoods Europe 2026, held from May 5 to May 7 in Barcelona, Spain, at booth 5D30, around a rigorous new validation phase. In collaboration with Liverpool John Moores University and StudySetGo, the company has initiated a double-blind, randomized controlled trial identified as NCT07528469. The study is designed to evaluate the efficacy of PeptiStrong in a cohort of 80 healthy adults between the ages of 60 and 85 over a 30-day period.
The trial methodology employs a direct comparison to challenge the current industry benchmark. One group of participants will consume a combination of 2.4g of PeptiStrong and 10g of whey protein, while the control group will consume 20g of whey protein alone. By isolating the effect of the 2.4g peptide dose against a standard whey-only regimen, Nuritas aims to quantify the additive or equivalent value of its plant-derived solution. The primary endpoint for the study is grip strength, a critical marker for overall muscle function in elderly populations. Secondary endpoints provide a comprehensive view of physical vitality, including walking speed, chair stand performance, balance, body composition, quality of life, fatigue levels, and specific inflammatory markers. The final results of this trial are expected to be released in the third quarter of 2026.
From AI Discovery to European Market Penetration
Until recently, the market for sarcopenia—the age-related loss of skeletal muscle mass and strength—was effectively a monopoly of clinical evidence held by whey protein. The shift currently underway is not merely a change in ingredient preference but a change in how bioactive compounds are discovered. Nuritas utilizes proprietary AI technology to identify specific bioactive peptides that can trigger physiological responses, allowing them to extract high-efficacy peptides from kidney beans. This AI-driven approach transforms PeptiStrong from a simple plant protein into a targeted bioactive tool.
This technological edge is already translating into commercial scale, with PeptiStrong integrated into more than 100 products globally. To support this growth, Nuritas is aggressively expanding its European logistics and distribution network to ensure the raw material reaches manufacturers across the continent. The company has secured new strategic partnerships with Alifarma for the Spanish and Portuguese markets and Faravelli for Italy. Furthermore, a partnership with Vivatis Pharma extends their reach into Poland, the Czech Republic, Slovakia, and the three Baltic states. This expansion ensures that the transition from animal-based to plant-based clinical evidence is matched by a robust supply chain.
For the product developer, this represents a fundamental shift in the raw material toolkit. The ability to offer a plant-based alternative that is backed by the same level of clinical rigor as whey allows for the creation of a new category of senior nutrition. The evidence is moving toward a reality where kidney bean peptides can be proposed as a scientifically valid substitute for whey in the fight against muscle atrophy.
The industry is moving toward a future where plant-based efficacy is no longer a secondary consideration but a primary clinical standard.
